# EARLY 3-months Aggrenox Treatment Started Within 24 Hrs of Ischemic Stroke Onset vs. After One Week 100 mg ASA

> **NCT00562588** · PHASE4 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 551 (actual)

## Conditions studied

- Cerebrovascular Accident

## Interventions

- **DRUG:** Aggrenox bid (ASA 25mg/Dipyridamole ER 200mg)
- **DRUG:** ASA 100 mg qd

## Key facts

- **NCT ID:** NCT00562588
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2009-02
- **Final completion:** —
- **Target enrollment:** 551 (ACTUAL)
- **Last updated:** 2014-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00562588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00562588, "EARLY 3-months Aggrenox Treatment Started Within 24 Hrs of Ischemic Stroke Onset vs. After One Week 100 mg ASA". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00562588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*